TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00830986

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty Implant (Scorpio®)
Description: Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty Implant (Scorpio®)
Description: Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
Study: NCT06179589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VS002A
Description: Amino acid based, glucose free ORS

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VS002A
Description: Amino acid based, glucose free ORS
Study: NCT00573131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV (in the vein) once on Day 1 and Day 29

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2 IV (in the vein) once on Day 1 and Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal resection
Description: Removal of esophagus after completion of chemotherapy and radiation therapy
Study: NCT03763188

Intervention type: OTHER
Intervention: Use of daily urinary urea excretion
Description: Weaning dialysis catheter
Study: NCT00573131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophageal resection
Description: Removal of esophagus after completion of chemotherapy and radiation therapy
Study: NCT03454139

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal transversus abdominis plane block
Description: Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
Study: NCT01095484

Intervention type: DRUG
Intervention: Rotigotine patch
Description: 1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
Study: NCT04370262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC + Intravenous Famotidine
Description: Standard of Care treatment plus IV famotidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC + Placebo
Description: Standard of Care treatment plus IV placebo
Study: NCT01118143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored oral health literacy instruction
Description: The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
Study: NCT04912128

Intervention type: DRUG
Intervention: Anlotinib
Description: Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.~Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
Study: NCT03393962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-EIEs
Description: 2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
Study: NCT00400387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin P Forte (dalteparin sodium)
Description: subcutaneous injection, once daily supported by multivitamine supplement and close monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Multivitamin supplement
Description: general pregnancy support by multivitamin supplementation and close monitoring
Study: NCT03090191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile vaccine
Description: Toxoid-based Clostridium difficile vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution (0.9% sodium chloride)
Study: NCT01251575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation
Study: NCT02253875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study: NCT00764894

Intervention type: DEVICE
Intervention: Foundation Knee
Description: Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
Study: NCT01174914

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ARV's + Placebo
Description: Patients continued ARV's plus a placebo nightly for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone + ARV's
Description: Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
Study: NCT02194881

Intervention type: DRUG
Intervention: CF patients with a G551D mutation and treated with Ivacaftor
Study: NCT01399827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Medication
Description: For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADHD Medication
Description: For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
Study: NCT02418403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Offer of money designed to overcome barriers to advance care planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational website
Description: Research-verson of the Prepare for your care website (www.prepareforyourcare.org)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational website
Description: Research-verson of the Prepare for your care website (www.prepareforyourcare.org)
Study: NCT02195115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-fat and low cholesterol diet
Study: NCT01331395

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Medicine
Description: Active arm will receive Acupuncture with their IVF cycle.
Study: NCT04535570

Intervention type: OTHER
Intervention: Indirect Calorimetry
Description: In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.

Intervention type: OTHER
Intervention: Indirect Calorimetry
Description: In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
Study: NCT02234401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi level pressure support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study: NCT04605679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Transplantation
Description: A HCV negative or previously successfully treated recipient with a HCV positive kidney graft
Study: NCT00003139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pilocarpine hydrochloride
Description: 5mg pilocarpine hydrochloride tablets
Study: NCT00439179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 1
Description: Weekly gem + GW572016, 1000mg/day (combination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 2
Description: Weekly gem + GW572016, 1500 mg/day (combination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 3
Description: GEMOX + GW572016 1000 mg/day (combination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 4
Description: GEMOX + GW572016 1500 mg/day (combination)
Study: NCT03270111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
Study: NCT00003139

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02522910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1000394 (Roniciclib) in combination with docetaxel
Description: The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
Study: NCT00708877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
Study: NCT03270111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Energy Diet
Description: Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Energy Diet
Description: Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Phone Calls
Description: Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Phone Calls
Description: Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
Study: NCT00994136

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: normal saline
Description: Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
Study: NCT04039802

Intervention type: PROCEDURE
Intervention: Single-stage surgery
Description: In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.

Intervention type: OTHER
Intervention: Two-stage surgery
Description: Two-stage surgery has already been performed, data will therefore be retrospectively collected
Study: NCT00170573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: 40 mg/m² biweekly
Study: NCT05586711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal estradiol 10 μg
Description: Vagifem® (estradiol), vaginal tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal DHEA 6.5 mg
Description: Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
Study: NCT03869736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: 1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
Study: NCT00878358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Study: NCT04107012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with clear aligner
Description: Included orthodontic treatment with clear aligner (eon Aligners)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment with clear aligner
Description: Included orthodontic treatment with clear aligner (eon Aligners)
Study: NCT01466114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol
Description: 4 capsules of 2 mg (total of 8 mg) PO QD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone
Description: Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
Study: NCT00878358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study: NCT05125120

Intervention type: OTHER
Group type: OTHER
Intervention: COGNİTİVE ORİENTATİTON DAİLY OCCUPATİONAL PERFORMANCE APPROACH
Description: Polatajko et al. (2001) developed the CO-OP approach, which is an occupation-oriented problem-solving approach that combines cognitive strategies to help children acquire motor abilities throughout daily tasks (9, 29). The CO-OP approach of therapy focuses on the goal or task at hand rather than the acquisition of functions in occupational performance. CO-OP is a 'deductive' or 'occupational performance-oriented' approach that focuses on the activity target selected throughout the therapy, as opposed to 'inductive' or 'impairment-focused' alternatives (13). As a verbal approach, CO-OP focuses on skill acquisition at the activity level and strives to provide children with global problem-solving skills. Necessary performance strategies specific to the child and the activity are determined with a customised programme (12, 30). Skill acquisition, cognitive strategy development, and adapting and transferring these acquired skills to daily life are the three key goals of the approach.
Study: NCT01466114

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progestin Placebo
Description: Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
Study: NCT02620865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antibody Therapy
Description: Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
Study: NCT04299633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: 2 x 150 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: 2 x 150 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: 2 x 150 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: 2 x 800 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Description: 2 x 667 mg oral gelcaps

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auryxia®
Description: 2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
Study: NCT01410591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8-mm covered stent group
Description: Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10-mm covered stent group
Description: Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
Study: NCT01375114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panax Ginseng
Description: 400 mg by mouth twice daily from Day 1-29.
Study: NCT01702012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almased Meal Replacement Powder
Description: Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-Based Lifestyle Intervention
Study: NCT02962635

Intervention type: DEVICE
Intervention: bioelectrical impedance measurement and biomarker measurement
Description: Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level

Intervention type: DEVICE
Intervention: bioelectrical impedance measurement and biomarker measurement
Description: Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
Study: NCT04441931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3832479
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study: NCT04524741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracardiac echocardiography
Description: 30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracardiac echocardiography
Description: 30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
Study: NCT05441969

Intervention type: OTHER
Intervention: No intervention/expousure
Description: No interventions/expousure since this is an observational study.

Intervention type: OTHER
Intervention: No intervention/expousure
Description: No interventions/expousure since this is an observational study.

Intervention type: OTHER
Intervention: No intervention/expousure
Description: No interventions/expousure since this is an observational study.
Study: NCT01837082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric carboxymaltose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo